These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19051133)

  • 41. [Secondary prevention of patients with ischaemic heart disease--the reduction of LDL cholesterol level and the regression of atherosclerosis].
    Bárczi G; Merkely B
    Lege Artis Med; 2007 Oct; 17(10):675-9. PubMed ID: 19227597
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenetics of statins therapy.
    Puccetti L; Acampa M; Auteri A
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):228-36. PubMed ID: 18221122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe?
    Seshasai SR; Ray KK
    Future Cardiol; 2009 Mar; 5(2):129-39. PubMed ID: 19371188
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ["The lower LDL cholesterol levels, the better" still valid. Negative/neutral conclusions of three studies on statins do not change the clinical practice].
    Olsson AG; Nilsson PM
    Lakartidningen; 2009 Mar 18-24; 106(12):854-7. PubMed ID: 19452786
    [No Abstract]   [Full Text] [Related]  

  • 48. The pharmacogenomics of statins.
    Gelissen IC; McLachlan AJ
    Pharmacol Res; 2014 Oct; 88():99-106. PubMed ID: 24365577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Statin drugs decrease the plasma level of coenzyme Q10 (ubiquinone) in the organism].
    Rákóczi K; Párdutz A; Vécsei L
    Ideggyogy Sz; 2007 Jul; 60(7-8):295-300. PubMed ID: 17713110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Statins with a perspective of lifelong therapy].
    Ertaş FS
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LDL-Cholesterol is the King.
    Goumas GS
    Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
    [No Abstract]   [Full Text] [Related]  

  • 52. Continuation of statin treatment and all-cause mortality: a population-based cohort study.
    Shalev V; Chodick G; Silber H; Kokia E; Jan J; Heymann AD
    Arch Intern Med; 2009 Feb; 169(3):260-8. PubMed ID: 19204217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical experience with ezetimibe/simvastatin in a Mediterranean population.
    Migdalis I; Efthimiadis A; Pappas S; Alexopoulos D; Vlasserou F; Mikhailidis DP
    Curr Med Res Opin; 2009 Oct; 25(10):2571-6. PubMed ID: 19739939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Lipid control in diabetic patients in Extremadura (Spain)].
    Roberto Robles N; Barroso S; Marcos G; Sánchez Muñoz-Torrero JF;
    Endocrinol Nutr; 2009 Mar; 56(3):112-7. PubMed ID: 19627723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment.
    Insull W
    Am J Med; 2009 Jan; 122(1 Suppl):S3-S14. PubMed ID: 19110086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of macular degeneration with statin use should be interpreted with caution.
    van Leeuwen R; Vingerling JR; de Jong PT
    BMJ; 2001 Dec; 323(7324):1308. PubMed ID: 11731401
    [No Abstract]   [Full Text] [Related]  

  • 58. Prevention and treatment of atherosclerosis: a practitioner's guide for 2008.
    Lewis SJ
    Am J Med; 2009 Jan; 122(1 Suppl):S38-50. PubMed ID: 19110087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia.
    Maki KC; Carson ML; Miller MP; Anderson WH; Turowski M; Reeves MS; Kaden V; Dicklin MR
    Eur J Clin Nutr; 2009 Aug; 63(8):1001-7. PubMed ID: 19209184
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new perspective on nonprescription statins: an opportunity for patient education and involvement.
    Fuster V
    Am J Cardiol; 2007 Sep; 100(5):907-10. PubMed ID: 17719344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.